Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald Marcus

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Joint Commission Journal on Quality and Patient Safety|November 9, 2007
Assessing quality obstetrical care: development of standardized measuresSusan Mann, Stephen Pratt, Paul Gluck, et al.
Journal of Psychopharmacology (Oxford, England)|January 13, 2006
Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled studyGary Sachs, Raymond Sanchez, Ronald Marcus, et al.
The International Journal of Neuropsychopharmacology|November 12, 2003
Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophreniaSiegfried Kasper, Mark N Lerman, Robert D McQuade, et al.
The American Journal of Psychiatry|September 4, 2008
A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophreniaRobert L Findling, Adelaide Robb, Margaretta Nyilas, et al.
The Journal of Clinical Psychiatry|March 6, 2025
Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the 5-Week, Randomized, Double-Blind, Placebo-Controlled EMERGENT TrialsInder Kaul, Amy Claxton, Sharon Sawchak, et al.
BMC Research Notes|July 20, 2014
Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label studyAnita H Clayton, Ross A Baker, John J Sheehan, et al.
Schizophrenia Research|March 13, 2026
Low incidence of extrapyramidal symptoms following treatment with a muscarinic agonist medication for schizophreniaSteven D Targum, Carolyn Watson, Amy Claxton, et al.
Addiction Biology|June 27, 2019
A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behaviorJermaine D Jones, Shanna Babalonis, Ronald Marcus, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Joint Commission Journal on Quality and Patient Safety|November 9, 2007
Assessing quality obstetrical care: development of standardized measuresSusan Mann, Stephen Pratt, Paul Gluck, et al.
Journal of Psychopharmacology (Oxford, England)|January 13, 2006
Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled studyGary Sachs, Raymond Sanchez, Ronald Marcus, et al.
The International Journal of Neuropsychopharmacology|November 12, 2003
Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophreniaSiegfried Kasper, Mark N Lerman, Robert D McQuade, et al.
The American Journal of Psychiatry|September 4, 2008
A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophreniaRobert L Findling, Adelaide Robb, Margaretta Nyilas, et al.
The Journal of Clinical Psychiatry|March 6, 2025
Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the 5-Week, Randomized, Double-Blind, Placebo-Controlled EMERGENT TrialsInder Kaul, Amy Claxton, Sharon Sawchak, et al.
BMC Research Notes|July 20, 2014
Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label studyAnita H Clayton, Ross A Baker, John J Sheehan, et al.
Schizophrenia Research|March 13, 2026
Low incidence of extrapyramidal symptoms following treatment with a muscarinic agonist medication for schizophreniaSteven D Targum, Carolyn Watson, Amy Claxton, et al.
Addiction Biology|June 27, 2019
A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behaviorJermaine D Jones, Shanna Babalonis, Ronald Marcus, et al.
Pageof 3